Single-Domain Antibodies As Therapeutics against Human Viral Diseases

In full-size formats, monoclonal antibodies have been highly successful as therapeutics against cancer and immune diseases. However, their large size leads to inaccessibility of some epitopes and relatively high production costs. As an alternative, single-domain antibodies (sdAbs) offer special advantages compared to full-size antibodies, including smaller size, larger number of accessible epitopes, relatively low production costs and improved robustness. Currently, sdAbs are being developed against a number of viruses, including human immunodeficiency virus-1 (HIV-1), influenza viruses, hepatitis C virus (HCV), respiratory syncytial virus (RSV), and enteric viruses. Although sdAbs are very potent inhibitors of viral infections, no sdAbs have been approved for clinical use against virial infection or any other diseases. In this review, we discuss the current state of research on sdAbs against viruses and their potential as therapeutics against human viral diseases.

[1]  Sara M. Johnson,et al.  Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection , 2017, The Journal of infectious diseases.

[2]  P. Hart,et al.  Unveiling a Drift Resistant Cryptotope within Marburgvirus Nucleoprotein Recognized by Llama Single-Domain Antibodies , 2017, Front. Immunol..

[3]  L. Sherwood,et al.  Intracellular Crosslinking of Filoviral Nucleoproteins with Xintrabodies Restricts Viral Packaging , 2017, Front. Immunol..

[4]  Wei Li,et al.  Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy , 2017, Scientific Reports.

[5]  B. Graham,et al.  Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab , 2017, Journal of Virology.

[6]  M. Kanekiyo,et al.  Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state , 2017, Nature Communications.

[7]  Janice M. Reichert,et al.  Antibodies to watch in 2017 , 2016, mAbs.

[8]  H. Ploegh,et al.  The Antiviral Mechanism of an Influenza A Virus Nucleoprotein-Specific Single-Domain Antibody Fragment , 2016, mBio.

[9]  T. Ying,et al.  New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments. , 2016, Current pharmaceutical biotechnology.

[10]  Zhiwei Chen,et al.  The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1 , 2016, Journal of Virology.

[11]  L. Maffey,et al.  Anti-VP6 VHH: An Experimental Treatment for Rotavirus A-Associated Disease , 2016, PloS one.

[12]  Nicholas A Meanwell,et al.  2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. , 2016, Journal of medicinal chemistry.

[13]  S. Van Gucht,et al.  Post-exposure Treatment with Anti-rabies VHH and Vaccine Significantly Improves Protection of Mice from Lethal Rabies Infection , 2016, PLoS neglected tropical diseases.

[14]  S. Whelan,et al.  Phenotypic lentivirus screens to identify functional single domain antibodies , 2016, Nature Microbiology.

[15]  L. Kwanten,et al.  Molecular mechanism of respiratory syncytial virus fusion inhibitors. , 2016, Nature chemical biology.

[16]  D. Filman,et al.  Five of Five VHHs Neutralizing Poliovirus Bind the Receptor-Binding Site , 2016, Journal of Virology.

[17]  G. Borgia,et al.  The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C , 2015, Expert opinion on drug discovery.

[18]  C. Palomo,et al.  Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection , 2015, Antimicrobial Agents and Chemotherapy.

[19]  A. Heredia,et al.  A novel small-molecule inhibitor of HIV-1 entry , 2015, Drug design, development and therapy.

[20]  D. Dimitrov,et al.  Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn , 2015, mAbs.

[21]  G. Weiner.  Building better monoclonal antibody-based therapeutics , 2015, Nature Reviews Cancer.

[22]  Louise van der Weerd,et al.  Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[23]  P. Srimanote,et al.  Humanized-VHH Transbodies that Inhibit HCV Protease and Replication , 2015, Viruses.

[24]  H. Ploegh,et al.  Intracellular Expression of Camelid Single-Domain Antibodies Specific for Influenza Virus Nucleoprotein Uncovers Distinct Features of Its Nuclear Localization , 2014, Journal of Virology.

[25]  G. Hansman,et al.  Nanobody Binding to a Conserved Epitope Promotes Norovirus Particle Disassembly , 2014, Journal of Virology.

[26]  Patrick Chames,et al.  Selection of Intracellular Single-Domain Antibodies Targeting the HIV-1 Vpr Protein by Cytoplasmic Yeast Two-Hybrid System , 2014, PloS one.

[27]  P. Desai,et al.  Antiviral Activity of a Single-Domain Antibody Immunotoxin Binding to Glycoprotein D of Herpes Simplex Virus 2 , 2014, Antimicrobial Agents and Chemotherapy.

[28]  P. Vanlandschoot,et al.  Protective Effect of Different Anti-Rabies Virus VHH Constructs against Rabies Disease in Mice , 2014, PloS one.

[29]  R. Weiss,et al.  Neutralisation of HIV-1 cell-cell spread by human and llama antibodies , 2014, Retrovirology.

[30]  D. Dimitrov,et al.  Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases , 2014, mAbs.

[31]  C. Ball,et al.  The Breadth of Cross Sub-Type Neutralisation Activity of a Single Domain Antibody to Influenza Hemagglutinin Can Be Increased by Antibody Valency , 2014, PloS one.

[32]  Liang Chen,et al.  Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors , 2014, Fundamental & clinical pharmacology.

[33]  W. Fiers,et al.  Single-Domain Antibodies Targeting Neuraminidase Protect against an H5N1 Influenza Virus Challenge , 2014, Journal of Virology.

[34]  Z. Sheng,et al.  Characterization of a Novel Influenza Virus in Cattle and Swine: Proposal for a New Genus in the Orthomyxoviridae Family , 2014, mBio.

[35]  D. Dimitrov,et al.  Interactions of IgG1 CH2 and CH3 Domains with FcRn , 2014, Front. Immunol..

[36]  J. Marcotrigiano,et al.  Structure of the Core Ectodomain of the Hepatitis C Virus Envelope Glycoprotein 2 , 2014, Nature.

[37]  D. Filman,et al.  Mechanism of Action and Capsid-Stabilizing Properties of VHHs with an In Vitro Antipolioviral Activity , 2014, Journal of Virology.

[38]  P. Srimanote,et al.  Humanized-VH/VHH that inhibit HCV replication by interfering with the virus helicase activity. , 2013, Journal of virological methods.

[39]  D. Moir,et al.  New Small Molecule Entry Inhibitors Targeting Hemagglutinin-Mediated Influenza A Virus Fusion , 2013, Journal of Virology.

[40]  C. Flexner,et al.  The antiretroviral drug pipeline: prospects and implications for future treatment research , 2013, Current opinion in HIV and AIDS.

[41]  L. Hammarström,et al.  Anti-rotavirus protein reduces stool output in infants with diarrhea: a randomized placebo-controlled trial. , 2013, Gastroenterology.

[42]  M. Oyama,et al.  Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. , 2013, The Journal of clinical investigation.

[43]  A. Meola,et al.  An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission , 2013, Hepatology.

[44]  F. Baldanti,et al.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody , 2013, Nature.

[45]  D. Dimitrov,et al.  Engineered Soluble Monomeric IgG1 CH3 Domain , 2013, The Journal of Biological Chemistry.

[46]  J. Mascola,et al.  Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites , 2013, Journal of Virology.

[47]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[48]  K. Bok,et al.  Recombinant Monovalent Llama-Derived Antibody Fragments (VHH) to Rotavirus VP6 Protect Neonatal Gnotobiotic Piglets against Human Rotavirus-Induced Diarrhea , 2013, PLoS pathogens.

[49]  Willem Bartelink,et al.  Isolation of Panels of Llama Single-Domain Antibody Fragments Binding All Nine Neuraminidase Subtypes of Influenza A Virus , 2013 .

[50]  L. Sherwood,et al.  Ebolavirus Nucleoprotein C-Termini Potently Attract Single Domain Antibodies Enabling Monoclonal Affinity Reagent Sandwich Assay (MARSA) Formulation , 2013, PloS one.

[51]  P. Zamore,et al.  Human Monoclonal Antibody MBL‐HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[52]  T. I. Ivanova,et al.  Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). , 2013, Antiviral research.

[53]  T. I. Ivanova,et al.  Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. , 2013, Antiviral research.

[54]  W. Weissenhorn,et al.  A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition , 2013, PLoS pathogens.

[55]  P. Srimanote,et al.  Cell Penetrable Humanized-VH/VHH That Inhibit RNA Dependent RNA Polymerase (NS5B) of HCV , 2012, PloS one.

[56]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[57]  J. Bouchet,et al.  Straightforward Selection of Broadly Neutralizing Single-Domain Antibodies Targeting the Conserved CD4 and Coreceptor Binding Sites of HIV-1 gp120 , 2012, Retrovirology.

[58]  D. Dimitrov,et al.  Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn , 2012, PloS one.

[59]  R. Purcell,et al.  Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees , 2012, PLoS pathogens.

[60]  D. Stock,et al.  General strategy for the generation of human antibody variable domains with increased aggregation resistance , 2012, Proceedings of the National Academy of Sciences.

[61]  R. Weiss,et al.  Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization , 2012, The Journal of experimental medicine.

[62]  U. Dietrich,et al.  Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice. , 2012, Vaccine.

[63]  S. Benichou,et al.  Single-Domain Antibody-SH3 Fusions for Efficient Neutralization of HIV-1 Nef Functions , 2012, Journal of Virology.

[64]  David W. Taylor,et al.  Structural Basis for Broad Detection of Genogroup II Noroviruses by a Monoclonal Antibody That Binds to a Site Occluded in the Viral Particle , 2012, Journal of Virology.

[65]  Guowei Wei,et al.  Potent Neutralization of Influenza A Virus by a Single-Domain Antibody Blocking M2 Ion Channel Protein , 2011, PloS one.

[66]  B. Schepens,et al.  Nanobodies®: new ammunition to battle viruses. , 2011, Antiviral research.

[67]  Kelly K. Lee,et al.  Capturing a Fusion Intermediate of Influenza Hemagglutinin with a Cholesterol-conjugated Peptide, a New Antiviral Strategy for Influenza Virus* , 2011, The Journal of Biological Chemistry.

[68]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[69]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[70]  C. Verrips,et al.  Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood–brain barrier , 2011, Neuroscience.

[71]  L. Hammarström,et al.  Lactobacilli producing bispecific llama-derived anti-rotavirus proteins in vivo for rotavirus-induced diarrhea. , 2011, Future microbiology.

[72]  R. Weiss,et al.  Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. , 2011, The Journal of infectious diseases.

[73]  S. Benichou,et al.  Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. , 2011, Blood.

[74]  D. Lavillette,et al.  Cell Entry of Enveloped Viruses , 2011, Advances in Genetics.

[75]  Adolfo García-Sastre,et al.  Virulence determinants of pandemic influenza viruses. , 2011, The Journal of clinical investigation.

[76]  R. Eisenberg,et al.  Cascade of Events Governing Cell-Cell Fusion Induced by Herpes Simplex Virus Glycoproteins gD, gH/gL, and gB , 2010, Journal of Virology.

[77]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[78]  S. Muyldermans,et al.  In vitro antiviral activity of single domain antibody fragments against poliovirus. , 2010, Antiviral research.

[79]  E. Vanstreels,et al.  An Intrabody Based on a Llama Single-domain Antibody Targeting the N-terminal α-Helical Multimerization Domain of HIV-1 Rev Prevents Viral Production* , 2010, The Journal of Biological Chemistry.

[80]  M. Jaramillo,et al.  Differential tumor-targeting abilities of three single-domain antibody formats. , 2010, Cancer letters.

[81]  N. Callewaert,et al.  Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of Pichia pastoris. , 2010, Journal of biotechnology.

[82]  A. West,et al.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10 , 2009, Proceedings of the National Academy of Sciences.

[83]  S. Muyldermans,et al.  General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold* , 2009, Journal of Biological Chemistry.

[84]  Seppo Ylä-Herttuala,et al.  Challenges in monoclonal antibody-based therapies , 2009, Annals of medicine.

[85]  D. Dimitrov.  Engineered CH2 domains (nanoantibodies) , 2009, mAbs.

[86]  D. Dimitrov,et al.  Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers , 2008, Proceedings of the National Academy of Sciences.

[87]  Geoffrey P Garnett,et al.  .‫املقالة‬ ‫لهذه‬ ‫الكامل‬ ‫النص‬ ‫نهاية‬ ‫يف‬ ‫الخالصة‬ ‫لهذه‬ ‫العربية‬ ‫الرتجمة‬ an Estimate of the Global Prevalence and Incidence of Herpes Simplex Virus Type 2 Infection , 2022 .

[88]  Z. Xiang,et al.  Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding. , 2008, Virology.

[89]  L. Saif,et al.  Llama-Derived Single-Chain Antibody Fragments Directed to Rotavirus VP6 Protein Possess Broad Neutralizing Activity In Vitro and Confer Protection against Diarrhea in Mice , 2008, Journal of Virology.

[90]  Yifan Cheng,et al.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies , 2008, Proceedings of the National Academy of Sciences.

[91]  Andrew Hayhurst,et al.  Rapid assembly of sensitive antigen-capture assays for Marburg virus, using in vitro selection of llama single-domain antibodies, at biosafety level 4. , 2007, The Journal of infectious diseases.

[92]  P. Khamrin,et al.  Characterization of a Broadly Reactive Monoclonal Antibody against Norovirus Genogroups I and II: Recognition of a Novel Conformational Epitope , 2007, Journal of Virology.

[93]  R. Kontermann,et al.  Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin* , 2007, Journal of Biological Chemistry.

[94]  Yaofeng Zhao,et al.  Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. , 2006, The Journal of infectious diseases.

[95]  Erik De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature Reviews Drug Discovery.

[96]  Lennart Hammarstrom,et al.  Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. , 2006, Vaccine.

[97]  Tomoyuki N. Tanaka,et al.  Genetic and antigenic diversity among noroviruses. , 2006, The Journal of general virology.

[98]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[99]  Jia-huai Wang,et al.  Design, Expression, and Immunogenicity of a Soluble HIV Trimeric Envelope Fragment Adopting a Prefusion gp41 Configuration* , 2005, Journal of Biological Chemistry.

[100]  Peter D. Kwong,et al.  Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.

[101]  R. Hegde,et al.  The P Domain of Norovirus Capsid Protein Forms Dimer and Binds to Histo-Blood Group Antigen Receptors , 2004, Journal of Virology.

[102]  L. James,et al.  Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. , 2004, Journal of molecular biology.

[103]  Christoph Grundner,et al.  Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[104]  Joseph Sodroski,et al.  Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. , 2002, AIDS research and human retroviruses.

[105]  A. Plückthun,et al.  Correlation between in Vitro Stability and in Vivo Performance of Anti-GCN4 Intrabodies as Cytoplasmic Inhibitors* , 2000, The Journal of Biological Chemistry.

[106]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[107]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[108]  R. Eisenberg,et al.  Monoclonal Antibodies to Distinct Sites on Herpes Simplex Virus (HSV) Glycoprotein D Block HSV Binding to HVEM , 1998, Journal of Virology.

[109]  L. Wyns,et al.  Comparison of llama VH sequences from conventional and heavy chain antibodies. , 1997, Molecular immunology.

[110]  D. Pfarr,et al.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. , 1997, The Journal of infectious diseases.

[111]  S. Muyldermans,et al.  Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. , 1994, Protein engineering.

[112]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[113]  Lawrence H. Pinto,et al.  Influenza virus M2 protein has ion channel activity , 1992, Cell.

[114]  P. T. Jones,et al.  Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli , 1989, Nature.

[115]  S. Holmberg,et al.  Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. , 1988, JAMA.

[116]  Jie Dong,et al.  Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. , 2018 .

[117]  A. D. de Fougerolles,et al.  Nanobodies®† as inhaled biotherapeutics for lung diseases , 2017, Pharmacology & therapeutics.

[118]  F. Veronese,et al.  The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.

[119]  S. Madhi,et al.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. , 2010, Lancet.

[120]  D. Burton,et al.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge , 2008, Nature Medicine.

[121]  Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. , 1998, Pediatrics.

[122]  R. Lamb,et al.  Orthomyxoviridae: The Viruses and Their Replication. , 1996 .